Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Hexin (Suzhou) Pharmaceutical Technology Co., Ltd

Clinicaltrial registered6 Nov 2026

Hexin (Suzhou) Pharmaceutical Technology Co., Ltd

6 Nov 2026: Trial registered · Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
6 Nov 2026
Title
Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors
Conditions
Soft Tissue Sarcoma, Non-small Cell Lung Cancer
Phase
Phase 1
Study Type
Interventional
Status
Enrolling By Invitation
Countries
China
Country
China
Reference
NCT07920822
Location
China
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Hexin (Suzhou) Pharmaceutical Technology Co., Ltd

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Hexin (Suzhou) Pharmaceutical Technology Co., Ltd in our registers.

More from China

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.